238 related articles for article (PubMed ID: 30983472)
1. A Low-Dose 4F-PCC Protocol for DOAC-Associated Intracranial Hemorrhage.
Berger K; Santibañez M; Lin L; Lesch CA
J Intensive Care Med; 2020 Nov; 35(11):1203-1208. PubMed ID: 30983472
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
[TBL] [Abstract][Full Text] [Related]
3. Tolerability and effectiveness of 4-factor prothrombin complex concentrate (4F-PCC) for warfarin and non-warfarin reversals.
Santibanez M; Lesch CA; Lin L; Berger K
J Crit Care; 2018 Dec; 48():183-190. PubMed ID: 30218958
[TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
5. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
[TBL] [Abstract][Full Text] [Related]
6. Four-factor prothrombin complex concentrate for life-threatening bleeds or emergent surgery: A retrospective evaluation.
Sin JH; Berger K; Lesch CA
J Crit Care; 2016 Dec; 36():166-172. PubMed ID: 27546767
[TBL] [Abstract][Full Text] [Related]
7. Impact of a Pharmacist-Driven Prothrombin Complex Concentrate Protocol on Time to Administration in Patients with Warfarin-associated Intracranial Hemorrhage.
Corio JL; Sin JH; Hayes BD; Goldstein JN; Fuh L
West J Emerg Med; 2018 Sep; 19(5):849-854. PubMed ID: 30202498
[TBL] [Abstract][Full Text] [Related]
8. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
[TBL] [Abstract][Full Text] [Related]
9. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Direct Oral Anticoagulant Reversal Agents in Intracranial Hemorrhage: A Systematic Review and Meta-analysis.
Chaudhary R; Singh A; Chaudhary R; Bashline M; Houghton DE; Rabinstein A; Adamski J; Arndt R; Ou NN; Rudis MI; Brown CS; Wieruszewski ED; Wanek M; Brinkman NJ; Linderbaum JA; Sorenson MA; Atkinson JL; Thompson KM; Aiyer AN; McBane RD
JAMA Netw Open; 2022 Nov; 5(11):e2240145. PubMed ID: 36331504
[TBL] [Abstract][Full Text] [Related]
12. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
13. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage.
Irizarry-Gatell VM; Bacchus MW; De Leo EK; Zhang Y; Lagasse CA; Khanna AY; Harris NS; Zumberg MS
Blood Coagul Fibrinolysis; 2024 Apr; 35(3):94-100. PubMed ID: 38358898
[TBL] [Abstract][Full Text] [Related]
14. High versus low fixed-dose four factor-prothrombin complex concentrate for warfarin reversal in patients with intracranial hemorrhage.
Compton F; Hall J; De Simone N; Usmani A; Sarode R; Burner J
Transfus Apher Sci; 2022 Oct; 61(5):103444. PubMed ID: 35414467
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Warfarin Reversal with Four-Factor Prothrombin Complex Concentrate for Subtherapeutic INR in Intracerebral Hemorrhage.
Rivosecchi RM; Durkin J; Okonkwo DO; Molyneaux BJ
Neurocrit Care; 2016 Dec; 25(3):359-364. PubMed ID: 27076286
[TBL] [Abstract][Full Text] [Related]
16. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
[TBL] [Abstract][Full Text] [Related]
17. Comparison of 4F-PCC and aPCC time to administration and outcomes for oral anticoagulant-related ICH.
Lin S; Cunningham B; Mullen C; Simon E; Bice D; Garlock J
Am J Emerg Med; 2022 Jun; 56():183-187. PubMed ID: 35405470
[TBL] [Abstract][Full Text] [Related]
18. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
[TBL] [Abstract][Full Text] [Related]
19. Low-dose Prothrombin Complex Concentrate for Warfarin-Associated Intracranial Hemorrhage with INR Less Than 2.0.
Zemrak WR; Smith KE; Rolfe SS; May T; Trowbridge RL; Hayes TL; Grindlinger GA; Seder DB
Neurocrit Care; 2017 Dec; 27(3):334-340. PubMed ID: 28660341
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
